Evidence map›Paper›PMID 38987289›Full record

ArticleNature communications2024

PARG is essential for Polθ-mediated DNA end-joining by removing repressive poly-ADP-ribose marks.

Umeshkumar Vekariya, Leonid Minakhin, Gurushankar Chandramouly, Mrityunjay Tyagi, Tatiana Kent, Katherine Sullivan-Reed, Jessica Atkins, Douglas Ralph, Margaret Nieborowska-Skorska, Anna-Mariya Kukuyan and 3 more

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Dynamic Assemblies in Genome Maintenance.Advances in experimental medicine and biology · 2026
    Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Umeshkumar Vekariya *Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, 19140, USA.
Leonid Minakhin *Thomas Jefferson University, Sidney Kimmel Cancer Center, Department of Biochemistry and Molecular Biology, Philadelphia, PA, 19107, USA.
Gurushankar ChandramoulyThomas Jefferson University, Sidney Kimmel Cancer Center, Department of Biochemistry and Molecular Biology, Philadelphia, PA, 19107, USA.
Mrityunjay TyagiThomas Jefferson University, Sidney Kimmel Cancer Center, Department of Biochemistry and Molecular Biology, Philadelphia, PA, 19107, USA.
Tatiana KentThomas Jefferson University, Sidney Kimmel Cancer Center, Department of Biochemistry and Molecular Biology, Philadelphia, PA, 19107, USA.
Katherine Sullivan-ReedFels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, 19140, USA.
Jessica AtkinsFels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, 19140, USA.
Douglas RalphThomas Jefferson University, Sidney Kimmel Cancer Center, Department of Biochemistry and Molecular Biology, Philadelphia, PA, 19107, USA.
Margaret Nieborowska-SkorskaFels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, 19140, USA.
Anna-Mariya KukuyanFels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, 19140, USA.
Hsin-Yao TangProteomics and Metabolomics Facility, The Wistar Institute, Philadelphia, PA, 19104, USA.ORCID 0000-0003-1838-018X
Richard T PomerantzThomas Jefferson University, Sidney Kimmel Cancer Center, Department of Biochemistry and Molecular Biology, Philadelphia, PA, 19107, USA. richard.pomerantz@jefferson.edu.ORCID 0000-0003-1194-9871
Tomasz SkorskiFels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, 19140, USA. tskorski@temple.edu.ORCID 0000-0002-3809-4538

Funding

Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Aaron Robert Goldman · 1985 to 2026
$75.9M
Targeting DNA repair to eradicate TKi-refractory/resistant CML and Ph+ALLR01CA186238 · NCI · TEMPLE UNIV OF THE COMMONWEALTH · PI SKORSKI, TOMASZ · 2014 to 2024
$4.5M
Divergent Functions of ERK Substrate Binding Domains in Pathogenesis of Myeloproliferative NeoplasmsR01CA283396 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI TOMASZ SKORSKI, DAVID L. WIEST · 2023 to 2026
$2.8M
PolQ as a novel therapeutic target in AMLR01CA244179 · NCI · TEMPLE UNIV OF THE COMMONWEALTH · PI POMERANTZ, RICHARD T, SKORSKI, TOMASZ · 2020 to 2024
$2.7M
Advancing Cancer Research through Comprehensive Proteomics and Metabolomics AnalysesR50CA221838 · NCI · WISTAR INSTITUTE · PI Hsin-Yao Tang · 2017 to 2026
$2.1M
Novel Mechanisms and Regulation of Mammalian Double-Strand Break RepairR35GM152198 · NIGMS · THOMAS JEFFERSON UNIVERSITY · PI Richard T Pomerantz · 2024 to 2026
$2.1M
MPN-inducing mutations as biomarkers of synthetic lethalityR01CA247707 · NCI · TEMPLE UNIV OF THE COMMONWEALTH · PI SKORSKI, TOMASZ · 2020 to 2024
$2.1M
Mechanisms of RNA-DNA repairR01GM137124 · NIGMS · THOMAS JEFFERSON UNIVERSITY · PI POMERANTZ, RICHARD T · 2020 to 2023
$1.5M
Leukemia and Lymphoma Society (Leukemia & Lymphoma Society) TRP 6628-21NCI NIH HHS P30 CA010815NCI NIH HHS R01 CA186238NCI NIH HHS R01 CA244179NCI NIH HHS R01 CA247707NCI NIH HHS R01 CA283396NCI NIH HHS R50 CA221838NIGMS NIH HHS R01 GM137124NIGMS NIH HHS R35 GM152198U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01GM137124U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA186238U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA244179U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA244707U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA283396
6 · The paper itself

Abstract

DNA polymerase theta (Polθ)-mediated end-joining (TMEJ) repairs DNA double-strand breaks and confers resistance to genotoxic agents. How Polθ is regulated at the molecular level to exert TMEJ remains poorly characterized. We find that Polθ interacts with and is PARylated by PARP1 in a HPF1-independent manner. PARP1 recruits Polθ to the vicinity of DNA damage via PARylation dependent liquid demixing, however, PARylated Polθ cannot perform TMEJ due to its inability to bind DNA. PARG-mediated de-PARylation of Polθ reactivates its DNA binding and end-joining activities. Consistent with this, PARG is essential for TMEJ and the temporal recruitment of PARG to DNA damage corresponds with TMEJ activation and dissipation of PARP1 and PAR. In conclusion, we show a two-step spatiotemporal mechanism of TMEJ regulation. First, PARP1 PARylates Polθ and facilitates its recruitment to DNA damage sites in an inactivated state. PARG subsequently activates TMEJ by removing repressive PAR marks on Polθ.

Indexed as

DNA Breaks, Double-StrandedDNA-Directed DNA PolymeraseDNA End-Joining RepairDNA Polymerase thetaPoly (ADP-Ribose) Polymerase-1AnimalsCarrier ProteinsDNADNA-Binding ProteinsDNA DamageGlycoside HydrolasesHEK293 CellsHumansNuclear ProteinsPoly Adenosine Diphosphate RibosePoly(ADP-ribose) PolymerasesCarrier ProteinsDNADNA-Binding ProteinsDNA-Directed DNA PolymeraseDNA Polymerase thetaGlycoside HydrolasesHPF1 protein, humanNuclear ProteinsPARP1 protein, humanPoly Adenosine Diphosphate Ribosepoly ADP-ribose glycohydrolasePoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerases

Identifiers

PMID38987289
PMCPMC11236980

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.